Drugs / BR9001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03718611 | Oct 2018 → Mar 2019 | rheumatoid arthritis | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR9001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03718611 ↗ |
| Route | Oral | “oral administration of BR9001 compared with BR900A” NCT03718611 ↗ |